Pfizer’s bladder cancer therapy meets main goal in late-stage study
(Reuters) -Pfizer’s experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on Friday following data from a late-stage study. The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients …
Pfizer’s bladder cancer therapy meets main goal in late-stage study Read More »










